跳至主要内容
临床试验/NCT00319163
NCT00319163已完成1 期

An Open-label, Single-dose, Randomized, 2-period, Crossover, Bioequivalence Study to Compare Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2006年5月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
26
试验地点
1
主要终点
Pharmacokinetic sampling over the course of 4 days following two different formulations of the same compound

研究概览

简要总结

Primary Objective: To determine the bioequivalence between the clinical batch process and the new processes for manufacturing LNG/EE.

Secondary Objective: To obtain additional safety and tolerability data concerning LNG/EE in healthy, cycling women.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women 18 - 35 years of age
  • Non-smokers

排除标准

  • History of thromboembolic disease
  • Prior adverse experiences with oral contraceptives

结局指标

主要结局

Pharmacokinetic sampling over the course of 4 days following two different formulations of the same compound

次要结局

  • Additional safety--clinical labs
  • electrocardiograms (ECGs)
  • vital signs
  • and adverse event recording over 4 days following administration of each formulation (LNG/EE)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验